From early humanity to treating today’s metabolic diseases

Neanderthals, Denisovans, and earlier populations of modern humans ventured into Central Eurasia at various moments in time across the last 500,000 years.

There is sparse archaeological and ancient molecular data from the region, however, limiting our understanding of the palaeoecology, hunting strategies, and hominin occupation histories across this vast geographic region. MiddleEarth allows us to generate such information for a few key archaeological sites spanning the last half million years.

Using state-of-the-art palaeoproteomics methods integrated with zooarchaeological research, we will provide insights into which animal species were hunted and the population dynamics of Pleistocene hunter-gatherers in Central Eurasia.

This will contribute unique and significant knowledge about the evolution and behaviour of our extinct cousins, the Neanderthals and Denisovans, as well as our own Pleistocene ancestors.

6.191.576 DKK

Recent years, the use of multiple-targeting compounds as treatment of metabolic diseases (obesity and type 2 diabetes) are greatly expanding.

Especially, many incretin-based compounds are emerging and highly effective in improving glycemic control and reducing body weight.

My field of expertise is the human physiology of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP), and recently, results of treatments with long-acting GIP-based compounds have indicated that the GIP physiology is more complex than understood so far.

Therefore, I will study the role of GIP in central and peripheral insulin sensitivity, glucose-distribution, and appetite- and nausea-regulation in humans. I will use hormone infusions of a GIP receptor agonist and antagonist during gold-standard glucose clamp techniques, whole-body PET-CT during oral ingestion of labelled glucose, and modern MRI techniques, and aim at describing the novel aspects of GIP physiology and therapeutic implications.

6.191.628 DKK